Cipla gets USFDA OAI status for Goa facility

Published On 2022-11-24 08:00 GMT   |   Update On 2022-11-24 07:40 GMT
Advertisement

Mumbai: Pharma major Cipla has announced that the company has received a communication from the US Food and Drug Administration (USFDA) that the classification of Company's Goa facility continues to be as Official Action Indicated ("OAI"). Official Action Indicated (OAI) means regulatory and/or administrative actions will be recommended.

"USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved. The Company has an ongoing de-risking plan in place for new product approvals," the company stated in a BSE filing.

Advertisement

"The Company will work closely with the USFDA and is committed to address these within the stipulated time," Cipla further stated.

Read also: USFDA issues 6 observations for Cipla Goa plant

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.

Read also: Cipla gets CDSCO Panel nod to manufacture, market COPD drug combination Aerosol for inhalation

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News